In glioblastoma-infected individuals who obtain anti-survivin immunotherapy, the lower levels of CD9 +/SVN + and CD9 +/GFAP +/SVN + exosomes have been associated with the sustained survival of patients (55). The gene discussed is CD9; the disease is glioblastoma.